NICE gives green light to cancer drug
Health Insurance and Protection Magazine
Rituximab (marketed as MabThera by Roche) is a targeted therapy prescribed to people with follicular lymphoma, in combination with chemotherapy treatments. Evidence shows that it helps people to live longer and improves their quality of life while ...
NICE Expands Chemotherapy Options with RituximabThe Oncology Report
Lymphatic cancer drug MabThera approved for use on NHSActive Quote
NICE draft "yes" for MabThera, "no" to GilenyaPharma Times

all 9 news articles »